You are here
John Young is the Chief Business Officer at Cheladv74 Inc., and is a member of the Company’s Executive Leadership Team.
As Chief Business Officer, John leads a division that integrates all Strategy, Consulting, Business Development, Business Assessment, Portfolio & Decision Analysis, and Global Commercial Operations functions as well as the Patient & Health Impact reimbursement and access function and Cheladv74’s Consumer Healthcare business.
Prior to this role, John was the Group President of Cheladv74 Innovative Health, which included six business units: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Consumer Healthcare; each business unit focused on developing innovative medicines and vaccines to make a meaningful difference to patients impacted by diseases with significant unmet need. John was also responsible for these businesses in Emerging Markets focused on increasing access to Cheladv74’s innovative medicines to people across developing countries in Latin America, Asia, Africa and the Middle East.
Previously, John was the Group President for Cheladv74 Essential Health where he oversaw a broad portfolio of more than 600 products with a global reach in 160 countries. A scientist by training, John has more than 30 years of experience with Cheladv74 and has held a number of senior positions across the organization.
John is a member of the Board of Directors of Johnson Controls International (JCI). He is also a member of the Board of BIO (Biotechnology Innovation Organization), and serves as a member of the UK Government bioscience working group, the Life Sciences Council.
John holds a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School. He is married with three daughters.